SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 369 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,206,366 | -72.3% | 13,964 | -77.3% | 0.00% | -75.0% |
| Q1 2024 | $7,956,042 | +47.0% | 61,451 | +9.5% | 0.01% | +33.3% |
| Q4 2023 | $5,411,587 | -53.7% | 56,119 | -41.8% | 0.01% | -57.1% |
| Q3 2023 | $11,690,584 | +7.4% | 96,447 | +1.5% | 0.02% | +10.5% |
| Q2 2023 | $10,884,023 | -26.0% | 95,041 | -11.0% | 0.02% | -29.6% |
| Q1 2023 | $14,714,100 | +196.4% | 106,752 | +178.6% | 0.03% | +145.5% |
| Q4 2022 | $4,964,365 | -49.3% | 38,311 | -56.7% | 0.01% | -50.0% |
| Q3 2022 | $9,790,000 | +105.5% | 88,575 | +39.4% | 0.02% | +120.0% |
| Q2 2022 | $4,765,000 | +121.3% | 63,550 | +131.4% | 0.01% | +150.0% |
| Q1 2022 | $2,153,000 | +59.5% | 27,459 | +83.3% | 0.00% | +33.3% |
| Q4 2021 | $1,350,000 | -21.1% | 14,984 | -19.0% | 0.00% | -25.0% |
| Q3 2021 | $1,710,000 | +27.7% | 18,489 | +7.4% | 0.00% | +33.3% |
| Q2 2021 | $1,339,000 | -7.3% | 17,221 | -3.6% | 0.00% | -25.0% |
| Q1 2021 | $1,444,000 | -76.9% | 17,864 | -51.2% | 0.00% | -75.0% |
| Q4 2020 | $6,242,000 | -15.2% | 36,593 | -30.2% | 0.02% | -23.8% |
| Q3 2020 | $7,363,000 | -10.9% | 52,433 | +1.7% | 0.02% | -19.2% |
| Q2 2020 | $8,263,000 | +57.5% | 51,539 | -4.0% | 0.03% | +36.8% |
| Q1 2020 | $5,248,000 | -13.1% | 53,707 | +14.7% | 0.02% | +5.6% |
| Q4 2019 | $6,039,000 | +52.3% | 46,825 | -11.1% | 0.02% | +80.0% |
| Q3 2019 | $3,964,000 | -52.4% | 52,666 | -3.9% | 0.01% | -63.0% |
| Q2 2019 | $8,323,000 | +32.8% | 54,780 | +4.1% | 0.03% | +28.6% |
| Q1 2019 | $6,268,000 | -35.5% | 52,611 | -14.3% | 0.02% | -40.0% |
| Q4 2018 | $9,712,000 | +4.6% | 61,411 | +6.9% | 0.04% | +2.9% |
| Q3 2018 | $9,282,000 | +28.8% | 57,471 | +5.4% | 0.03% | +41.7% |
| Q2 2018 | $7,207,000 | +109.1% | 54,518 | +17.2% | 0.02% | +84.6% |
| Q1 2018 | $3,446,000 | +88.1% | 46,506 | +41.3% | 0.01% | +116.7% |
| Q4 2017 | $1,832,000 | +80.8% | 32,917 | +47.4% | 0.01% | +50.0% |
| Q3 2017 | $1,013,000 | – | 22,338 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Evolutionary Tree Capital Management, LLC | 68,937 | $5,138,000 | 3.04% |
| Avoro Capital Advisors LLC | 2,150,000 | $160,240,000 | 2.77% |
| Casdin Capital, LLC | 550,000 | $40,992,000 | 1.22% |
| TOBAM | 371,107 | $27,659,000 | 1.18% |
| Ikarian Capital, LLC | 455,900 | $33,978,000 | 1.14% |
| Eventide Asset Management | 697,156 | $51,959,000 | 0.77% |
| FOX RUN MANAGEMENT, L.L.C. | 4,902 | $365,000 | 0.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 31,500 | $2,348,000 | 0.62% |
| Sivik Global Healthcare LLC | 20,000 | $1,491,000 | 0.54% |
| Rock Springs Capital Management LP | 328,750 | $24,502,000 | 0.54% |